ArticleFrontiers in oncology2026
Assessing the impact of phosphodiesterase 5 inhibitors on survival in men after treatment for rectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Phosphodiesterase type 5 inhibitors (PDE5Is) facilitate the attainment and maintenance of erections during sexual stimulation. Because erectile dysfunction is common after rectal cancer treatment, PDE5Is are frequently used in this population. We assessed whether PDE5I use was associated with overall survival after rectal cancer treatment. Methods: Utilizing data from Clalit Health Services in Israel, the analysis included 1,552 patients, with 256 users of PDE5Is. Survival differences were evaluated using categorical and non-parametric tests, Cox proportional hazards models, and propensity score matching to control for confounding variables. Results: PDE5I use was found to be significantly associated with improved survival, with a hazard ratio of 0.455 (p<0.001). The survival benefit persisted after adjusting for covariates and implementing matching procedures. Conclusions: These findings suggest a potential association consistent with a protective effect of PDE5I use as well as duration of use on survival in rectal cancer patients, warranting further investigation into underlying mechanisms and clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.